Ac-SDKP is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-05-09. Numbers and descriptions here follow the published literature rather than marketing material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Typical form for short synthetic peptides |
| Solubility class | Freely soluble in water and aqueous buffer | Dissolution aided by gentle mixing, not vigorous shaking |
| Typical storage temperature | −20 °C, desiccated | −80 °C used for long-term holding |
| Common analytical method | Reverse-phase HPLC with UV detection near 214 nm | Identity confirmed separately by mass spectrometry |
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming varies between suppliers and publications |
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
=== Other uses === PVDF is used for specialty monofilament fishing lines, sold as fluorocarbon replacements for nylon monofilament. The surface is harder, so it is more resistant to abrasion and sharp fish teeth. Its refractive index is lower than nylon, which makes the line less discernible to fish eyes. It is also denser than nylon, making it sink faster towards fish. PVDF is used for specialty roofing coatings to improve UV resistance and increase roof color retention.
==== Officer of the Order of the British Empire (OBE) ==== Military Commander Trefor Morgan Fox, Royal Navy, C037045S. Commander Christopher Robert Hollingworth, Royal Navy, C041543F. Colonel Andrew Glenn David Lock, Royal Marines, N029023U. Commander Lucy Jane Ottley, Royal Navy, V030919T. Commander Ian Hayden Richardson, Royal Navy, C038366T. Commander Jamie Duncan Wells, Royal Navy, C039514F. Captain Allan Thomas Youp, Royal Navy, C038889U. Lieutenant Colonel Nicholas Paul Andrew, Royal Regiment of Artillery, 537949. Lieutenant Colonel Tracy-Louise Appleyard, Royal Army Medical Corps, 540495. Colonel Edward Hugh James Carter, 532335. Lieutenant Colonel Ewan Christian Noble Harris, The Royal Welsh, 545550. Lieutenant Colonel Timothy Matthew Holmes, Corps of Royal Electrical and Mechanical Engineers, 546527. Colonel Matthew Gordon Timothy Lewis, 554319. Lieutenant Colonel (now Acting Colonel) John Andrew Lyons, Royal Corps of Signals, 549561. Lieutenant Colonel Craig David Pope, Royal Army Medical Corps, 549180. Colonel Nigel Offley Crewe-Read, , 545207. Colonel Thomas Woolley, 551152. Colonel Nicholas George Charles Yardley, 544447. Wing Commander Erica Jane Ferguson, Royal Air Force, 2629012K. Wing Commander Matthew Elfed Lewis, Royal Air Force, 5208143G. Wing Commander Stephen McCleery, Royal Air Force, 2635078L. Wing Commander Alison Morton, Royal Air Force, W996632T. Air Commodore Patrick James Shea-Simonds, Royal Air Force, 5208323H. Group Captain Paul Andrew Weaver Smith, Royal Air Force, 8024057B.
== Methods == Different methods in detrital zircon analysis yield different results. Generally, researchers would include the methods/ analytical instruments they used within their studies. There are generally three categories, which are the instrument(s) used for zircon analysis, their calibration standards and instrument(s) used for zircon imagery. Details are listed in Table 1.
This is a list of logistics occupations, including occupations involved in logistics, supply chain management, warehousing, distribution, and the transportation of passengers and goods. Transportation and material-moving occupations include workers in road transport, rail transport, air transportation, and maritime transport, as well as workers involved in freight transport, stock, and material handling.
=== The Human Chimera Prohibition Act === On 11 July 2005, a bill known as The Human Chimera Prohibition Act was introduced into the United States Congress by Senator Samuel Brownback; however, it died in Congress sometime in the next year. The bill was introduced based on findings that science had progressed to the point where human and nonhuman species could be merged to create new forms of life. Because of this, ethical issues might arise as the line blurred between humans and other animals, and according to the bill with this blurring of lines would come a show of disrespect for human dignity. The final claim brought up in The Human Chimera Prohibition Act was that there was an increasing amount of zoonotic diseases, and that the creation of human-animal chimeras might allow these diseases to reach humans. On 22 August 2016, another bill, The Human-Animal Chimera Prohibition Act of 2016, was introduced to the United States House of Representatives by Christopher H. Smith. It identified a human-animal chimera as:
Sources: en.wikipedia.org
A review of the UKPDS, Action to Control Cardiovascular Risk in Diabetes (ACCORD), Advance and Veterans Affairs Diabetes Trials (VADT) estimated that the risks of the main complications of diabetes (diabetic retinopathy, diabetic nephropathy, diabetic neuropathy, and macrovascular disease) decreased by about 3% for every 1 mmol/mol decrease in HbA1c. However, a trial by ACCORD designed specifically to determine whether reducing HbA1c below 42 mmol/mol (6.0 DCCT %) using increased amounts of medication would reduce the rate of cardiovascular events found higher mortality with this intensive therapy, so much so that the trial was terminated 17 months early. Practitioners must consider patients' health, their risk of hypoglycemia, and their specific health risks when setting a target HbA1c level. Because patients are responsible for averting or responding to their own hypoglycemic episodes, their input and the doctors' assessments of the patients' self-care skills are also important. Persistent elevations in blood sugar (and, therefore, HbA1c) increase the risk of long-term vascular complications of diabetes, such as coronary disease, heart attack, stroke, heart failure, kidney failure, blindness, erectile dysfunction, neuropathy (loss of sensation, especially in the feet), gangrene, and gastroparesis (slowed emptying of the stomach). Poor blood glucose control also increases the risk of short-term complications of surgery, such as poor wound healing.
phosphorylation Aside from cleavage, phosphorylation is perhaps the most important chemical modification of proteins. A phosphate group can be attached to the sidechain hydroxyl group of serine, threonine and tyrosine residues, adding a negative charge at that site and producing an unnatural amino acid. Such reactions are catalyzed by kinases and the reverse reaction is catalyzed by phosphatases. The phosphorylated tyrosines are often used as "handles" by which proteins can bind to one another, whereas phosphorylation of Ser/Thr often induces conformational changes, presumably because of the introduced negative charge. The effects of phosphorylating Ser/Thr can sometimes be simulated by mutating the Ser/Thr residue to glutamate. glycosylation A catch-all name for a set of very common and very heterogeneous chemical modifications. Sugar moieties can be attached to the sidechain hydroxyl groups of Ser/Thr or to the sidechain amide groups of Asn. Such attachments can serve many functions, ranging from increasing solubility to complex recognition. All glycosylation can be blocked with certain inhibitors, such as tunicamycin. deamidation (succinimide formation) In this modification, an asparagine or aspartate side chain attacks the following peptide bond, forming a symmetrical succinimide intermediate. Hydrolysis of the intermediate produces either aspartate or the β-amino acid, iso(Asp). For asparagine, either product results in the loss of the amide group, hence "deamidation".
== History == SR-17018 was patented in 2016 and first described in the scientific literature by Laura Bohn and colleagues at the Scripps Research Institute in Jupiter, Florida in 2017. The drug was encountered as a novel designer drug online by 2023. Analogues like brorphine and SR-14968 have also been encountered as novel designer drugs. Brorphine is said to not be popular among recreational users as it produces little euphoria but reportedly still has potential for severe respiratory depression. In 2024, discussion of SR-17018 on the social media website Reddit suddenly dramatically increased and the drug emerged as an informal treatment for opioid discontinuation and withdrawal. On July 1, 2026, the United States Drug Enforcement Administration (DEA) signed a letter of intent to temporarily place SR-17018 under Schedule I of the Controlled Substances Act. This will likely take effect on July 31, 2026. There has been opposition to the announcement, for instance by the Students for Sensible Drug Policy (SSDP).
In Brazil, the constitution establishes six different police agencies for law enforcement: Federal Police Department, Federal Highway Police, Federal Railroad Police, Federal, District and State Penal Police (included by the Constitutional Amendment No. 104, of 2019), Military Police and Civil Police. Of these, the former three are affiliated with federal authorities, the latter two are subordinate to state governments and the Penal Police can be subordinated to the federal or state/district government. All police forces are overseen by the executive branch of the federal or state governments. The National Public Security Force also can act in public disorder situations arising anywhere in the country. The country has high levels of violent crime, such as gun violence and homicides. In 2022, the United Nations Office on Drugs and Crime (UNODC) estimated an intentional homicide rate of 21.1 per 100,000 inhabitants. The number considered acceptable by the World Health Organization (WHO) is about 10 homicides per 100,000 inhabitants. In 2025, Brazil recorded 34,086 homicides, down from 38,374 in 2024, and from a record 63,880 in 2017. Homicide rates vary regionally. While in São Paulo the homicide rate registered in 2025 was 5.4 per 100,000 inhabitants, in Ceará it was 32.6 per 100,000 inhabitants. The national homicide rate for 2025 was 16 per 100,000 inhabitants, the lowest in over a decade. Brazil also has high levels of incarceration.
Sources: en.wikipedia.org
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.
Not necessarily. Some vendors use the name for the full 43-residue protein, while others apply it to a short actin-binding fragment or to a related tetrapeptide. The sequence should be confirmed from documentation rather than assumed from the label.
No thymosin beta-4 fragment holds marketing approval as a medicine in major jurisdictions. Material offered for sale is typically labelled for laboratory research only.
Dry lyophilized powder is usually kept frozen, desiccated, and out of direct light. Sealed vials are not opened until needed, because moisture uptake can degrade short peptides. Longer archival storage is often done at lower temperatures than routine working stock.